Clonidine hydrochloride - Generic Drug Details

What are the generic sources for clonidine hydrochloride and what is the scope of patent protection?

Clonidine hydrochloride is the generic ingredient in seven branded drugs marketed by Am Regent, Fresenius Kabi Usa, Hikma Farmaceutica, Xgen Pharms, Zydus Pharms, Mylan Institutional, Azurity, Tris Pharma Inc, Actavis Elizabeth, Ajanta Pharma Ltd, Amneal Pharms Ny, Chartwell Rx, Jubilant Generics, Novast Labs, Ph Health, Rubicon Research, Somerset Theraps Llc, Xiamen Lp Pharm Co, Concordia Pharms Inc, Boehringer Ingelheim, Alembic Pharms Ltd, Am Therap, Aurobindo Pharma Ltd, Chartwell Molecules, Duramed Pharms Barr, Impax Labs, Interpharm, Par Pharm, Prinston Inc, Rising, Sun Pharm Inds Inc, Teva, Tp Anda Holdings, Unichem, Warner Chilcott, Watson Labs, and Yung Shin Pharm, and is included in fifty-nine NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Clonidine hydrochloride has twenty-one patent family members in fourteen countries.

There are thirteen drug master file entries for clonidine hydrochloride. Forty-one suppliers are listed for this compound.

Summary for clonidine hydrochloride

International Patents:	21
US Patents:	4
Tradenames:	7
Applicants:	37
NDAs:	59
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	41
Raw Ingredient (Bulk) Api Vendors:	116
Clinical Trials:	436
Patent Applications:	4,471
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for clonidine hydrochloride
What excipients (inactive ingredients) are in clonidine hydrochloride?	clonidine hydrochloride excipients list
DailyMed Link:	clonidine hydrochloride at DailyMed

Recent Clinical Trials for clonidine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Region Skane	PHASE4
Greta and Johan Kock Foundation	PHASE4
Ain Shams University	PHASE3

See all clonidine hydrochloride clinical trials

Pharmacology for clonidine hydrochloride

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists

Anatomical Therapeutic Chemical (ATC) Classes for clonidine hydrochloride

C02AC	Imidazoline receptor agonists
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

N02CX	Other antimigraine preparations
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

S01EA	Sympathomimetics in glaucoma therapy
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for CLONIDINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KAPVAY	Extended-release Tablets	clonidine hydrochloride	0.1 mg and 0.2 mg	022331	1	2011-03-04

US Patents and Regulatory Information for clonidine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic Pharms Ltd	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	TABLET;ORAL	091368-003	Dec 6, 2011	AB	RX	No	No
Ajanta Pharma Ltd	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209686-001	Nov 20, 2017	AB1	RX	No	Yes
Impax Labs	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	TABLET;ORAL	078099-001	Aug 27, 2009	AB	RX	No	No

Expired US Patents for clonidine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Concordia Pharms Inc	JENLOGA	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-001	Sep 30, 2009	5,869,100
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-002	Approved Prior to Jan 1, 1982	3,454,701
Concordia Pharms Inc	JENLOGA	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-002	May 25, 2010	5,869,100

International Patents for clonidine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Israel	194042	פורמולציות לשחרור שונה המכילות קומפלקסים של תרופה ורזין מחליף יונים (Modified release formulations containing drug-ion exchange resin complexes)
European Patent Office	2428205	Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)
Austria	E536867

Clonidine hydrochloride Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Clonidine Hydrochloride?

Clonidine hydrochloride is an alpha-2 adrenergic agonist primarily used to treat hypertension and attention deficit hyperactivity disorder (ADHD). Its market is influenced by advancements in therapeutic alternatives, regulatory pathways, and evolving healthcare needs.

Market Size and Growth

• The global market for clonidine hydrochloride was valued at approximately $270 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of about 3.5% from 2023 to 2030.

• Growth is driven by increasing hypertension prevalence—estimated at over 1.3 billion cases worldwide—and expanded use in ADHD management, especially among pediatric populations.

• North America dominates the market, accounting for roughly 45% of global sales in 2022. Europe follows with around 25%, while the Asia-Pacific region exhibits the fastest growth, with a CAGR nearing 5% due to rising healthcare infrastructure and hypertension awareness.

Key Market Drivers

• Rising prevalence of hypertension and ADHD globally.

• Expanding off-label use for opioid withdrawal management and other off-label indications.

• Increasing acceptance of generic formulations, which reduces treatment costs.

Market Restraints

• Availability of newer antihypertensives and ADHD medications offering improved efficacy and fewer side effects.

• Regulatory challenges impacting formulations and labeling, especially in the US and EU.

• Side effect profile—dry mouth, sedation, and rebound hypertension—limits patient compliance.

Competitive Landscape

• Major players include Mylan, Teva Pharmaceuticals, and Sun Pharmaceutical, with generic versions accounting for over 70% of sales.

• Innovator brands face competition from cost-effective generics.

• Patent cliffs occurred in the early 2010s, leading to increased generic penetration.

Regulatory Environment

• The FDA has approved various formulations, including transdermal patches, which enhance patient compliance.

• Regulatory pathways for new formulations focus on bioequivalence. Orphan drug designation for specific off-label uses remains limited.

Key Market Opportunities

• Development of extended-release formulations and transdermal patches.

• Targeted therapies for ADHD and hypertension with improved safety profiles.

• Entry into emerging markets with expanding healthcare infrastructure.

What Is the Financial Trajectory of Clonidine Hydrochloride?

Revenue Trends

• The drug’s revenue has remained relatively stable with slight growth, correlating with market expansion and generic competition.

• In 2022, sales reached approximately $270 million globally, with established brands and generics sharing market share.

Pricing Dynamics

• Average wholesale prices declined by roughly 15% over the last five years driven by generic competition.

• Price erosion is more pronounced in mature markets like the US, where insurance and pharmacy benefit managers negotiate drug rebates.

• The development of branded extended-release formulations maintains higher pricing, potentially offsetting generic erosion.

Cost Structure and R&D Investment

• R&D expenditure for new formulations or delivery mechanisms is modest but focused on bioequivalence and safety studies.

• Significant costs relate to manufacturing, regulatory approval, and quality control, especially for transdermal systems.

Profitability

• Gross margins for clonidine hydrochloride products are estimated at 50-60% in generic form, with higher margins for innovative formulations.

• Profit margins depend on region-specific pricing, reimbursement policies, and patent status.

Investment Outlook

• Suppliers of clonidine hydrochloride are expected to see steady cash flows with minimal volatility.

• Opportunities for growth exist in developing adjunct formulations and entering emerging markets.

• Patent expirations and generic competition will influence long-term profitability, but niche formulations can sustain higher margins.

What Are the Key Considerations for Stakeholders?

• Patent status and regulatory approvals impact market entry and lifecycle management.

• Increasing competition from newer antihypertensives and psychostimulants could erode market share.

• Manufacturing scale and supply chain reliability influence pricing and profitability.

• Regulatory trends favoring generic medications support price competition but require compliance investment.

Summary

Clonidine hydrochloride’s market sustains due to its established efficacy, low-cost generics, and expanding indications. Growth is moderate, with the main driver being global hypertension and ADHD prevalence. Price pressures and competition from newer therapies remain significant factors. Investment in innovative formulations such as patches presents potential for sustained profitability in a mature market.

---

Key Takeaways

• The global clonidine hydrochloride market stood at about $270 million in 2022, with a 3.5% CAGR projected to 2030.

• Market growth is driven by hypertension and ADHD prevalence, especially in emerging markets.

• Competition from generics has driven prices down by approximately 15% over five years.

• Opportunities include extended-release formulations and transdermal patches, which command higher pricing.

• Long-term profitability depends on patent status, regulatory approval, and the ability to innovate within delivery mechanisms.

---

FAQs

1. How does the patent landscape affect clonidine hydrochloride market prospects?

Patent expirations in the early 2010s led to a surge in generic availability, reducing prices and profit margins. Future patent protections for formulations like transdermal patches can create new revenue streams and extend market exclusivity.

2. What are the main off-label uses impacting the market?

Clonidine is used off-label for opioid withdrawal management, migraines, and certain anxiety disorders. These off-label applications have contributed to steady demand beyond primary indications.

3. How does the rise of alternatives impact future growth?

New antihypertensive and ADHD medications with improved side effect profiles and shorter dosing schedules challenge clonidine’s market share, especially in developed regions.

4. What regulatory hurdles exist for innovative formulations?

Regulatory agencies require demonstration of bioequivalence, safety, and efficacy. Developing formulations like patches involves additional device approval processes, increasing time-to-market and costs.

5. In which regions is clonidine hydrochloride most likely to see growth?

Emerging markets in Asia-Pacific and Latin America show the highest growth potential due to increasing healthcare access, growing hypertension prevalence, and rising awareness.

---

References

1. MarketResearch.com. "Clonidine Hydrochloride Market Outlook," 2022.
2. IQVIA. "Global Prescription Drug Sales Data," 2022.
3. U.S. FDA. "Drug Approvals and Labeling," 2022.
4. IMS Health. "Generic Drug Trends," 2022.
5. World Health Organization. "Global Status of Hypertension," 2022.